Small molecule · Degrader of MDM2 · developed by Kymera Therapeutics
KT-253 is a small molecule protein degrader that binds MDM2 and the E3 ubiquitin ligase, targeting MDM2 for proteasomal degradation. This restores p53 transcriptional activity and p53-mediated tumor cell apoptosis. It is being studied in myeloid malignancies, acute lymphocytic leukemia, lymphomas and advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05775406 | Phase 1 | Myeloid Malignancies | Completed | KYMR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Lymphocytic LeukemiaAdvanced Solid TumorsLymphomasMyeloid Malignancies
Updated Oct 18, 2026. Something wrong or missing? Report it on the KYMR page.
See KYMR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KYMR catalysts and pipeline →